Leading Edge Genomic Services & Solutions

Novogene Europe Relocates its Sequencing Centre to Cambridge Science Park

CAMBRIDGE, UK, Oct 17, 2019 – Novogene Europe has upgraded and relocated its first European Sequencing Centre to TusPark UK’s new Bio-Innovation Centre in the Cambridge Science Park. The grand opening ceremony of Novogene’s new facility was held at 2 pm, 11th October 2019.

The move to the Bio-Innovation Centre has enabled Novogene’s Cambridge Sequencing Centre to expand its operation and continue to provide unsurpassed turnaround times and guaranteed data quality. With a professional team recruited from all over the world, the Centre offers leading-edge Next Generation Sequencing (NGS) services and solutions for all types of projects. The lab is now equipped with a variety of platforms, including an automatic system for library preparation, multiple NovaSeq 6000s and High Performance Computing Clusters. Novogene Cambridge Sequencing Centre is now capable of performing more than 280,000 human WGS analysis per year.

Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise, and more advanced sequencing capacity in the world. The Novogene Europe subsidiary was established in 2014 to address the European market for NGS and expand Novogene’s business in Europe. Novogene Europe now provides leading edge services and solutions to customers in over 30 countries in Europe.

Novogene’s comprehensive service offering at its Cambridge Sequencing Centre includes human genome sequencing, plant and animal genome sequencing, transcriptome sequencing, metagenome sequencing, and lanes sequencing. Additional services are planned for the near future enabling Novogene Europe to provide even more optimized solutions for clients based on their research goals.

Ms. Tingting Zhou, the general manager of Novogene Europe, said, “The relocation of Novogene Cambridge Sequencing Centre helps us to improve our services, which is a significant development milestone of Novogene Europe. This means that we can deliver higher levels of NGS services and help our clients to solve the practical problems in their research. Our customers encouraged us to expand our services as we have always been trying to maximize the benefits for our customers. I also believe that our Cambridge Sequencing Centre will continue to thrive.”

“We are delighted to welcome Novogene to the Bio-Innovation Centre,” said Dr. David Chaplin, TusPark UK’s General Manager of the Bio-Innovation Centre. “Emerging technologies like NGS play critical roles in human health, environmental protection, plant and animal breeding and microbial remediation. The relocation of Novogene Cambridge Sequencing Centre is a fantastic new addition to the Cambridge Science Park. It’s our pleasure to establish a long-term relationship and grow together with Novogene.”

About Novogene Europe

Novogene Europe, established in 2014, is a Subsidiary of Novogene. It makes significant contributions to advancing human heath, agriculture, and environmental protection. Over 300 scientific research institutes and biotechnology companies in Europe rely on the powerful technologies and services of Novogene Europe. With leading-edge platforms, well developed bioinformatics pipelines, extensive experience in NGS, and the support from skilled employees, Novogene Europe has become the most competitive NGS provider in Europe.

About Cambridge Science Park

The Cambridge Science Park was established in 1970 by Trinity College – the largest of the colleges of the University of Cambridge. Trinity owns the freehold of the Cambridge Science Park which comprises 1.7 million sq ft of high technology and laboratory buildings set in 152 acres of mature parkland. Today, the Park is home to 7000 people at over 130 companies ranging from exciting start-ups to some of the world’s leading technology businesses.

Contact:

Ms. Tingting Zhou
General Manager
Novogene Europe
tingting.zhou@novogene-europe.com

Dr. Yan Wang
Tuspark UK
Operations Manager
yan.wang@tuspark.co.uk

Chipscreen and Novogene enter a strategic partnership for companion diagnostics development

Chipscreen Biosciences Co., Ltd. (Chipscreen, Stock Symbol: 688321. SH) and Novogene Co., Ltd. (Novogene) recently announced a strategic partnership for companion diagnostics (CDx) development. Under the agreement, Novogene will develop a CDx for Chipscreen’s anti-tumor drug candidate Chiauranib (CS2164), and will provide molecular testing services during Chipscreen’s clinical trials on Chiauranib.

Chiauranib is a multi-kinase inhibitor designed and developed by Chipscreen to target several novel molecules in three signaling pathways. Its anti-tumor effects stem from the simultaneous inhibition of angiogenesis and mitosis as well as the modification of the tumor microenvironment. According to the agreement, Chipscreen will leverage Novogene’s professional CDx development team and its CAP-accredited lab in Tianjin, China, to accelerate the clinical development of Chiauranib. “The collaboration between Chipscreen and Novogene will help select the right patients for the clinical development of Chiauranib in several tumor types, including ovarian cancer, small cell lung cancer, liver cancer, and non-Hodgkin’s lymphoma.” Said Dr. Zhiqiang Ning, Executive Vice President of Chipscreen, “In the US and many European countries, the co-development of innovative therapeutics and companion diagnostics is already a common practice because it has proven to increase the efficiency and success rate of drug development. We really hope our partnership with Novogene will help implement this idea and practice in China to benefit more patients faster.”

CDx not only increases the efficiency and success rate of drug development, but also makes treatment more personalized and effective. This is particularly important in the development of targeted therapies and immunotherapies in oncology. “Novogene offers a one-stop-shop molecular CDx development platform, has the experience of successfully developing and registering oncology in vitro diagnostics in China and operates a diagnostics sales network that covers the entire domestic market. We are thus perfectly positioned to provide pharma partners with comprehensive, value-added CDx services.” Said Dr. Jeff Cheng, Chief Scientific Officer of Novogene, “This partnership between two companies that are each leading player in their own field is an exciting joint effort on the orchestrated development, registration and commercialization of an innovative targeted therapy and its CDx in China.”

About Chipscreen

In 2001, Chipscreen Biosciences was founded in Shenzhen, specializing in the research and development of original small molecule drugs. With the self-created “integrated drug discovery and early evaluation platform based on chemical genetics” as its core competitiveness, Chipscreen Biosciences has now become one of China’s leading innovative drug enterprises, forming a modern biomedicine group company in Shenzhen, as its headquarters / research and development center / GMP production base, Chengdu, as a regional headquarter / research and development center / GMP production base, Beijing clinical research center and Shanghai commercial center. At present, the company has developed a number of original new drug product lines for tumors, diabetes, and endocrine and autoimmune diseases. In December 2014, the original anti-tumor new drug Chidamide was approved by the China Food and Drug Administration for marketing. Shenzhen Chipscreen Biosciences Co., Ltd. (Stock Symbol: 688321.SH) has been listed on the SSE STAR Market on August 12, 2019.

About Novogene

Founded in March 2011 in Beijing Zhonguangcun Life Science Park, Novogene specializes in the application of cutting-edge molecular biology technologies and high-performance computing in life science research and human health. Currently providing services to clients in more 60 countries and 6 continents, Novogene has become a global leader in the field of genomic sequencing and bioinformatics services.
With a deep understanding of the drug R&D process, rich project management experience and a strong commitment to data quality, Novogene provides fully integrated services for preclinical, translational, clinical and diagnostic R&D needs from pharmaceutical companies across the world in our strategically located CAP-accredited and CLIA-certified labs across the globe.

Mission Bio Launches in China, Announces Distribution Partnership with Novogene

Deal brings single-cell genomics to China and accelerates Mission Bio’s mission to predict and prevent cancer relapse on a global scale

SOUTH SAN FRANCISCO, Calif. (July 10 2019) Mission Bio, the pioneer in targeted single-cell DNA analysis and precision genomics, today announced that it has launched sales in China through a distribution agreement with Novogene, a leading provider of genomic services and solutions globally. The deal brings the Mission Bio Tapestri® Platform to the rapidly expanding Chinese market.

China is one of the world’s largest next-generation sequencing (NGS) markets, with enormous opportunities for genomics. Thanks to greater investment into the region’s healthcare infrastructure, the market is poised to explode: recent reports project the country’s DNA sequencing market will reach $2.7 billion by 2022, up from $1.1 billion in 2017. Further, the in vitro diagnostics (IVD) market is expected to double by 2022, growing from $3 billion in 2017.

“The demand for innovative and impactful technologies has required Novogene to bring new products to our customers,” said Ruiqiang Li, Ph.D., founder and CEO of Novogene. “The Mission Bio Tapestri Platform has advantages over current offerings, including increased resolution down to 0.1 percent. It is synergistic to the sequencing we offer, and we are excited to be able to offer this unique technology to our customers.”

The Mission Bio Tapestri Platform is the only single-cell targeted DNA solution available to more precisely identify cancer cell mutation profiles. Tapestri’s unique ability to sensitively detect rare cancer subclones and co-occurring cancer mutations offer a precise way to measure therapy response and disease progression.

“We are excited about our partnership with Novogene and increasing our reach into the China market,” said Darrin Crisitello, Chief Commercial Officer of Mission Bio. “Novogene is highly regarded globally across the industry with reach into key accounts that will have significant interest in the Tapestri Platform. The adoption of this targeted single-cell DNA analysis has been strong in other parts of the world, and we expect the same uptake in the Chinese market.”

Most recently, researchers at UCSF and Penn leveraged the single-cell technology to track and monitor cancer evolution, revealing the potential for more impactful, dynamic therapies in patients with Acute Myeloid Leukemia (AML). The study, published in Cancer Discovery, is the first-ever study using single-cell DNA analysis to reveal how cancer evolves in response to targeted treatment.

To learn more about Mission Bio and how it’s moving precision medicine forward, visit missionbio.com.

About Mission Bio

Mission Bio delivers targeted solutions for high impact applications with the Tapestri Platform. The Tapestri Platform is the industry’s first single-cell DNA sequencing platform, enabling precise detection of heterogeneity in disease progression and treatment response. Application areas include blood cancers, solid tumors, and genome editing validation. The platform includes an instrument, consumables and software, which plug seamlessly into existing NGS workflows. LabCorp’s Covance Drug Development business will be the first global contract research organization to offer services on the Mission Bio Tapestri Platform, supporting biopharmaceutical customers in their need for faster, more precise clinical trials.

The company’s Tapestri Platform was also honored as a Top 10 Innovation of 2018 by The Scientist, as well as utilized by researchers at MD Anderson Cancer Center (MDACC) for the largest single-cell study completed to date. With Mission Bio, researchers have a highly sensitive, targeted, and customizable solution to move precision medicine forward.

About Novogene Corporation

Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and one of the largest sequencing capacities in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 2,214 employees, multiple locations around the world, 49 NGS related patents, and over 250 publications in top tier journal such as Nature and Science, the company has rapidly become a world-leader in NGS services. For more information, visit https://en.novogene.com/.

Novogene Receives CAP accreditation for its Med NGS Clinical Lab in Tianjin, China

TIANJIN, CHINA – March 19, 2019 – Novogene, a leading provider of genomic services and solutions, announced today that the Tianjin Novogene Med Lab – NGS Clinical Lab for genomic testing has successfully renewed its CAP accreditation, passing rigorous on-site inspection by experts from the College of American Pathologists (CAP) in recognition of the high standards of excellence established since its first accreditation in February 2017.

The College of American Pathologists is a US non-governmental organization that is widely considered the leader in laboratory quality assurance. Based on standards and guidance from the Clinical & Laboratory Standards Institute (CLSI) and the Clinical Laboratory Improvement Amendments (CLIA) of 1988, the CAP has created detailed checklists containing a core set of requirements which apply to all areas performing laboratory tests and procedures. Through its laboratory quality solutions programs, the CAP improves patient safety and advances the quality of pathology and laboratory service through education, standard setting and ensuring laboratories meet or exceed regulatory requirements.

Founded on June 23rd, 2014, the Tianjin Novogene Med Lab – NGS Clinical Lab is a modern, large-scale and independent clinical laboratory established in accordance with the standards of provincial medical inspection institutes issued by the Ministry of Health in China. It was approved by the Municipal Health and Family Planning Commission in December 2014 for the application of clinical gene amplification technology. Since March 7th, 2016, the Med Lab has been operating according to the international authoritative clinical laboratory quality certification system-the CAP -and passed the professional on-site inspection by CAP experts on February 10th, 2017, making it the first CAP-accredited NGS clinical lab in mainland China. After two years of effective operation and continuous improvement of its quality system, the Tianjin Novogene Med Lab – NGS Clinical Lab has once again passed the on-site inspection and successfully maintained its CAP accreditation.

“With the renewal of our CAP accreditation, Novogene continues to be globally recognized as a high-quality clinical service provider,” said Dr. Jeff Cheng, Chief Scientific Officer and Global Head of BioPharmaceutical Services at Novogene. “We strive to offer our clients best-in-class genomic solutions to advance research in human health.”

Novogene’s continuing accreditation signals that the lab has achieved universally accepted benchmarks for the standardization and accuracy of its quality management system, experimental technique level, bioinformatics analyses and clinical interpretation ability. This achievement is an important milestone in further establishing Novogene as a leading global provider of genomic services and solutions.

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple branches around the world, 49 NGS-related patents, as well as over 950 publications in top-tier journals such as Nature and Science, the company has rapidly become a world leader in NGS services.

Novogene Receives CFDA Approval for NovoFocus NSCLC CDx Test

Beijing, China – August 15, 2018 – Tianjin Novogene Bioinformatics Technology Company LTD, a fully-owned subsidiary of Novogene Co., received CFDA approval for its NovoFocus NSCLC CDx Test today. This is a next-generation sequencing (NGS)-based diagnostic test that simultaneously analyzes tumor samples for multiple genomic mutations associated with several CFDA-approved targeted therapies for non-small cell lung cancer (NSCLC), which accounts for ~80% of all lung cancers in China.

The NovoFocus NSCLC CDx Test was developed on the Thermo Fisher Ion Proton™ sequencing platform (approved by CFDA as “DA8600” in January 2017 for the diagnosis of cancer and inherited diseases). The reagent kits for sample processing and library construction, as well as the data analysis and result reporting software system, were developed by Novogene. Following this CFDA approval, results from the sequencing and analysis of three genes, EGFR, ALK and ROS1, can be used to identify NSCLC patients who may be eligible for treatment by CFDA-approved targeted therapies Gefitinib (IRESSA®), Osimertinib (TAGRISSO®) and Crizotinib (XALKORI®), respectively. Results on the other three genes, KRAS, BRAF and PIK3CA, can be considered by clinicians together with other test results and the patient’s disease characteristics during clinical decision making.

Figure: CFDA announcement for the approval of the NovoFocus NSCLC CDx Test (red box: translated to English below)

Ion Proton™ is a registered trademark of Thermo Fisher; IRESSA® and TAGRISSO® are registered trademarks of AstraZeneca; and XALKORI® is a registered trademark of Pfizer.

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple branches around the world, 49 NGS-related patents, as well as over 950 publications in top-tier journals such as Nature and Science, the company has rapidly become a world leader in NGS services. For more information, visit https://en.novogene.com/.

Novogene Establishes its First European Genomic Sequencing Center in Cambridge, UK

Cambridge, UK – May 21, 2018 – Novogene, a leading global provider of genomics services and solutions, today announced its first genomic sequencing center in Europe. The Novogene UK Genomic Sequencing Center will be established at the Babraham Research Campus in Cambridge in the United Kingdom. The center will provide an important base for Novogene to serve its European customers and contribute to human health across Europe.

The Novogene UK Genomic Sequencing Center will be equipped with a full automation system and the latest Illumina NovaSeq and supercomputing platforms. Establishing this facility will enable Novogene to provide cutting-edge next-generation sequencing and bioinformatics services and solutions to scientists at European universities, research institutes, pharmaceutical companies, and biotechnology companies.

“We are proud to set up our first European laboratory at the Babraham Research Campus,” said Dr. Ruiqiang Li, Founder and CEO of Novogene. “Our UK lab is our first step towards addressing the increasing demand from our European customers and will help us contribute to advancing human health, environmental protection, and plant and animal breeding in the United Kingdom and the whole of Europe.”

Derek Jones, CEO of Babraham Bioscience Technologies, which is responsible for the management and development of the Babraham Research Campus added: “I am extremely pleased to welcome Novogene to the Babraham Research Campus. The role of genomics is rapidly evolving and the Cambridge Cluster has become a hub for innovation in this area, attracting leader organizations, like Novogene, to locate here. Close proximity to academic and commercial collaborateors – both on campus and within the wider cluster – is hugely beneficial to the organizations based here and results in innovative and ground-breaking research that will ultimately benefit us all.”

About Babraham Research Campus
Babraham Bioscience Technologies Ltd (BBT) is responsible for the management and commercial development of the Babraham Research Campus.

The Babraham Research Campus is distinct in its co-location of 60 bioscience companies with the Babraham Institute, a world-renowned research organization which receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC).

The aim of the campus is to support UK bioscience through academic research, but also with facilities and capabilities for early-stage and growing commercial organizations. The campus provides companies laboratory and office space, networking and collaboration opportunities, together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.

The campus is managed and developed by BBT on behalf of the BBT shareholders, BBSRC and the Babraham Institute. For more information please visit: www.babraham.com.

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple branches around the world, 49 NGS-related patents, as well as over 950 publications in top-tier journals such as Nature and Science, the company has rapidly become a world leader in NGS services. For more information, visit https://en.novogene.com/.

Contact:
Tingting Zhou
General Manager
Novogene Europe
zhoutingting@novogene.com

The Babraham Research Campus
Derek Jones
CEO
Babraham Bioscience Technologies Ltd
derek.jones@babraham.co.uk

The University Medical Center Groningen and Novogene Announce the Start of the 10K Metagenome Project

Groningen, Netherlands and Beijing, China – October 31, 2017 — A research group led by Professor Cisca Wijmenga from the University Medical Center Groningen (UMCG) and Novogene, a leading global provider of genomic services and solutions, today announced a partnership to start the 10K Metagenome Project to further study population-based metagenomics.

The 10K Metagenome Project is initiated by Professor Cisca Wijmenga, Professor Rinse Weersma, Associate Professor Jingyuan Fu, and Associate Professor Alexandra Zhernakova from UMCG. This project aims to analyze 10,000 gut microbiomes from a large, deeply phenotyped population-based cohort in the Netherlands by using next-generation sequencing to study interactions between the microbiome and exogenous and intrinsic host factors. This follows a successful proof of concept study that was published last year in Science (Zhernakova et al., 2016). As part of the partnership, Novogene will provide next-generation sequencing for stool samples collected by UMCG and deliver high-quality data for each metagenome.

“Metagenomic shotgun sequencing allows us to discover intrinsic and exogenous factors that correlate with shifts in the microbiome composition and functionality,” said Professor Cisca Wijmenga, Spinoza Prize winner at UMCG. “Combined with the 8000 phenotypes present in the biobank, this rich dataset will enhance our understanding of which strains and pathways prevent or cause disease, a first step in translational research”.

“By leveraging the largest sequencing capacity in the world as well as our rich experience with next-generation sequencing technology, Novogene is taking an active role in accelerating genomic studies from all over the world,” said Ms. Tingting Zhou, General Manager of Novogene Europe. “It’s a great honor to partner with distinguished scholars from UMCG on the 10K Metagenome Project. This unprecedented study will shed more light on gut metagenomics, and therefore provide a better understanding of human health. We are proud to be part of it.”

About UMCG
The University Medical Center Groningen (UMCG) was established in 2005 as a joint activity of the University of Groningen and the Academic Hospital Groningen (AZG). At present, the UMCG is one of the largest hospitals in the Netherlands and the largest employer in the Northern Netherlands. More than 12,000 employees provide patient care, are involved in medical education and performing cutting-edge scientific research, and are focused on “healthy and active aging”.

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple branches around the world, 49 NGS-related patents, as well as over 950 publications in top-tier journals such as Nature and Science, the company has rapidly become a world leader in NGS services. For more information, visit https://en.novogene.com/.

Contact:

Professor Cisca Wijmenga, UMCG
C.Wijmenga@umcg.nl

Professor Rinse Weersma, UMCG
r.k.weersma@umcg.nl

Weiyan Peng
Business Development Director
Novogene Europe
pengweiyan@novogene.com

Novogene prepares to enter the proteomics service market with the addition of five Thermo Scientific™ Q Exactive™ HF-X Mass Spectrometers

San Diego and Beijing, October 5, 2017 — Novogene, a leading provider of genomic services and solutions with cutting edge next-generation sequencing and bioinformatics expertise, recently announced the stationing of five Thermo Scientific™ Q Exactive™ HF-X Hybrid Quadrupole-Orbitrap™ Mass Spectrometers in its Tianjin laboratory. With this addition, the company will be able to begin offering proteomic services. Novogene is committed to building the world’s most advanced biological mass spectrometry center to provide customers with comprehensive and in-depth multi-omics solutions.

The Q Exactive™ HF-X Mass Spectrometer uses a high-capacity transfer tube for maximum ion loading, an electrodynamic ion funnel that accommodates and transmits ions over a broader mass range, and a high-field Thermo Scientific™ Orbitrap™ mass analyzer. The platform significantly improves the scanning speed to an unprecedented 40Hz, the sensitivity by up to 10 times, as well as the quantitative reproducibility and sample throughput of protein detection. These features make the Q Exactive™ HF-X better-suited for the in-depth study of proteomics of complex biological samples.

As a world-leading sequencing services provider, Novogene has shown unsurpassed strength and capacity in genomic services and solutions since its founding in 2011. With the addition of five high-resolution Q Exactive™ HF-X Mass Spectrometers, Novogene has marked its transition from a genetic sequencing service company to a full service, multi-omics solution provider to better serve its customers worldwide and to enhance the quality of scientific research and precision medicine.

“Novogene has been focusing on applying high-throughput sequencing technologies in the field of scientific research over the years, and has become the world’s largest next-generation and SMRT sequencing center,” said Dr. Zhi Jiang, President of Novogene. “Proteomics is closer to the dynamic changes in life activities and phenotypic variation. With the continuous development of the mass spectrometry technology, we have seen a growing demand for multi-omics research. We have had a long-term collaboration in genomic sequencing and molecular diagnostics with Thermo Fisher already and we look forward to this in-depth cooperation to jointly promote the development of proteomics in the life sciences research with Thermo Fisher.”

Novogene’s services cover scientific research, cancer gene detection and genetic testing areas. With the largest sequencing capacity and gene interpretation capabilities worldwide, Novogene has provided genomic sequencing and bioinformatics data analysis services to global customers in research universities, research institutes, hospitals, pharmaceutical R&D companies and agricultural companies. Novogene is committed to promoting the rapid development and application of proteomics in the scientific research services area using the advanced high-resolution mass spectrometry platforms and solutions from Thermo Fisher.

Contacts:

Joyce Peng, Ph.D.
Global Marketing Director and General Manager
San Diego, California
+1-626-222-5584
joyce.peng@novogene.com

The Global Ant Genomics Alliance Announces Partnership With Novogene To Advance The Genomic Study Of Ants Around The World

July 18, 2017, Copenhagen, Denmark and Beijing, China –– The Global Ant Genomics Alliance (GAGA; http://antgenomics.dk/), an international collaboration of researchers from a variety of fields and institutions from across the globe, is partnering with Novogene Co., LTD, a leading global provider of genomic services and solutions, to make a significant leap forward in understanding the genomics of ants.

The partnership aims to obtain around 300 genomes, covering all ant genera across the world, to facilitate reconstruction of the evolutionary history and ecological resilience of this important social insect family. Under the partnership Novogene will provide PacBio sequencing for the ant species collected by the GAGA consortium and deliver high quality long-reads data, with up to 50x coverage generating 15 gigabases of long-read data for each ant genome.

“PacBio sequencing technology will allow almost gap-less genome assemblies that should make sure that ant genomes generated under GAGA will meet future quality standards of journals and repositories,” said Guojie Zhang, professor at the University of Copenhagen and head of the GAGA consortium. “The technology also requires only small amounts of DNA, significantly alleviating the biomass constraints for sampling material and enabling genome sequencing for almost all rare and small ants.”

“We are pleased to be partnering with The Global Ant Genomics Alliance on this important research endeavor,” said Dr. Ruiqiang Li, Founder, Chairman, and CEO of Novogene. “By applying our PacBio sequencing capabilities to the project we look forward to generating a robust database on the ant genome and helping advance the knowledge and understanding of this diverse species.”

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and one of the largest sequencing capacities in the World. Novogene pursues scientific excellence, strong commitment to customer service, and unsurpassed data quality to help our clients realize their research goals in the rapidly developing world of genomics. With 1,800 employees, multiple locations around the world, 49 NGS related patents, and over 250 publications in top-tier journal such as Nature and Science, Novogene has rapidly become a world-leader in NGS services. For more information, visit https://en.novogene.com/.

About The Global Ant Genomics Alliance
The Global Ant Genome Project is a growing international collaboration of researchers from a variety of fields and institutions across the world. This global project on ant genomics will provide a comprehensive dataset of the genomic diversity of the world’s ant genera. Based on the comparative analysis of these data, we will be able to understand the global trends of ant evolution and narrow down the genetic features that have been particularly relevant for the diversification and astonishing evolutionary success of ants. Researchers are interested in joining the consortium
can submit their research interest via http://antgenomics.dk/call-for-gaga-projects-and-subprojects/. For more information, click here.

Contact:
Joyce Peng, Ph.D.
Global Marketing Director and General Manager
Novogene Corporation
+1-626-222-5584
joyce.peng@novogene.com

Novogene Will Use Pacific Biosciences SMRT Technology to Build Novo-Disease SV Genomes Database

–First database of long-read whole genome sequencing data–

San Diego, July 18, 2017 — Novogene announced today it plans to use Pacific Biosciences SMRT® technology to build a comprehensive Chinese genome database, Novo-Disease SV Genomes. The database will consist of long-read sequencing data of 1000 Chinese genomes from a variety of disease types. As the first ever database of long-read human whole genome sequencing information, Novo-Disease SV Genomes will be a breakthrough step in the understanding of the human genome and in the field of precision medicine.

As a pioneer in the genomics field, Novogene has previously constructed the Novo-Zhonghua Genomes database, a population-specific genome database that consists of whole genome sequencing data on 2,500 normal Chinese genomes. The Novo-Zhonghua Genomes database reveals a large amount of SNPs and InDels that can be used for disease-specific variant annotation.

Databases such as Novo-Zhonghua Genomes, constructed with a large amount of genome sequencing data, lay the foundation for precision medicine. However, a genome database consisting of short-read sequencing data alone often misses the information on most structural variants (SVs), the changes in the chromosomal structure that can be linked to disease susceptibility.

Pacific Biosciences’ Single Molecule, Real-Time (SMRT) sequencing technology has the advantage of uniform coverage across all genomes. Whole genome sequencing with PacBio Systems helps provide complete and accurate views of all types of genomic variation, revealing SNPs/SNVs, structural variants, mobile elements, haplotypes, epigenetics, and variants in low-complexity regions. Furthermore, the isoform sequencing (Iso-Seq®) method with the Sequel System generates full-length cDNA sequences, which can be used to profile the full complexity of the human transcriptome and discover novel genes, isoforms, and gene fusion events.

“By applying PacBio’s SMRT technology to the construction of our Novo-Disease SV Genomes database, we will be able to apply long-read sequencing that can detect disease variants often missed by short-read sequencing,” stated Ruiqiang Li, Ph.D., Founder and CEO of Novogene. “This more revealing and informative database should greatly improve our understanding of disease mechanisms and contribute to the development of novel diagnostic and therapeutic approaches.”

About Novogene Corporation
Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and one of the largest sequencing capacities in the world. Novogene pursues scientific excellence, strong commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly developing world of genomics. With 1,800 employees, multiple locations around the world, 49 NGS related patents, and over 250 publications in top tier journal such as Nature and Science, Novogene has rapidly become a world-leader in NGS services. For more information, visit https://en.novogene.com/

Contacts:
Joyce Peng, Ph.D.
Global Marketing Director and General Manager
San Diego, California
+1-626-222-5584
joyce.peng@novogene.com